Mabion (WAR:MAB) Tax Provision : zł-8.6 Mil (TTM As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Mabion Tax Provision?

Mabion's tax provision for the three months ended in Sep. 2024 was zł0.0 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2024 was zł-8.6 Mil.

Mabion Tax Provision Historical Data

The historical data trend for Mabion's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabion Tax Provision Chart

Mabion Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

12.16

1.15

-8.63

Mabion Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Tax Provision	Get a 7-Day Free Trial															-	-8.63	-	-	-

Mabion Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-8.6 Mil.

Mabion Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabion SA (WAR:MAB) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

N/A

Address

ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050

Website

https://www.mabion.eu

Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.